Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro

Figure 1

Antileukemic potential of atorvastatin (A), cladribine + mafosfamide combination (CM), or atorvastatin in combination with cladribine + mafosfamide (CM + A) evaluated on the basis of cell viability (a) and apoptosis induction (b–d) examination after 24 and 48 h CLL cell exposure. Proapoptotic activity of the tested drugs was evaluated by Permeable/Dead Cell Apoptosis Kit (b), DNA content analysis (c), and PE active caspase-3 apoptosis kit (d). the results were statistically significant at .

(a) Cell viability by Membrane Permeable/Dead Cell Apoptosis Kit

(b) Apoptosis induction by Membrane Permeable/Dead Cell Apoptosis Kit

(c) Apoptosis induction on the basis of DNA content

(d) Apoptosis induction on the basis of caspase-3 activation in PBMCs from exemplary patient number 13